Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Humanigen, Inc. (HGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1730+0.0191 (+12.41%)
At close: 04:00PM EDT
0.1801 +0.01 (+4.10%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.1539
Open0.1500
Bid0.1658 x 1100
Ask0.1780 x 1100
Day's Range0.1476 - 0.1770
52 Week Range0.1476 - 8.3800
Volume4,288,547
Avg. Volume9,466,855
Market Cap15.953M
Beta (5Y Monthly)-1.09
PE Ratio (TTM)N/A
EPS (TTM)-3.1140
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Humanigen, Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Newsfile

    Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML

    Additional Clinical Sites Expected to Enroll CMML Patients in Australia Short Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - September 12, 2022) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, ("Humanigen") and the South Australian Health and Medical Research Institute ("SAHMRI") today announced an expansion of the ongoing development Precision Approach to Chronic Myelomonocytic Leukemia ("PREACH-M") study of lenzilumab in chronic myelomonocytic leukemia ("CMML

  • Newsfile

    Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022

    Short Hills, New Jersey--(Newsfile Corp. - September 7, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab ("LENZ®"), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor ("GM-CSF"), today announced presentation and participation in two healthcare focused investor conferences in September 2022. Details of the presentation and panel participation are as follows:H.C. Wainwright 24t

  • Business Wire

    Humanigen Reports Second Quarter 2022 Financial Results

    SHORT HILLS, N.J., August 12, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.

Advertisement
Advertisement